iOnctura is a company that develops bio-molecules intended for the treatment of cancer and fibrosis. Its bio-molecules include novel therapeutics that modulate key culprits of immunosuppression in the tumor microenvironment. The company aims to improve immune checkpoint therapies by developing novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes.